PFIZER, INC. |
Market Closed -
Other stock markets
|
After market 20:00:00 | |||
| 28.82 USD | +1.55% |
|
28.84 | +0.07% |
| 06:15am | Pfizer offers up to $250 million to settle thousands of Zantac cancer lawsuits, FT reports | RE |
| 05-13 | Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank... |  |
ETFs positioned on Pfizer, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.89% | 121 M€ | +8.33% | - | |
| 0.88% | 204 M€ | +10.54% | ||
| 0.85% | 8 M€ | +6.12% | - | |
| 0.85% | 744 M€ | +8.72% | ||
| 0.84% | 9 M€ | +10.87% | ||
| 0.82% | 104 M€ | +10.67% | ||
| 0.78% | 265 M€ | +6.18% | - | |
| 0.75% | 1 M€ | +0.04% | ||
| 0.75% | 559 M€ | +14.30% | ||
| 0.75% | 1,848 M€ | +18.39% | - | |
| 0.72% | 2,517 M€ | +12.80% | - | |
| 0.70% | 57 M€ | +20.91% | - | |
| 0.65% | 8 M€ | +5.48% | - | |
| 0.63% | 7 M€ | +6.22% | - | |
| 0.60% | 283 M€ | +19.75% | ||
| 0.60% | 50 M€ | +10.93% | ||
| 0.60% | 273 M€ | -.--% | ||
| 0.60% | 1,174 M€ | +23.54% | ||
| 0.60% | 655 M€ | -.--% | - | |
| 0.59% | 22 M€ | +14.86% | ||
| 0.54% | 414 M€ | +12.60% | - | |
| 0.54% | 1,006 M€ | -.--% | - | |
| 0.54% | 3 M€ | +15.16% | - | |
| 0.54% | 13 M€ | -.--% | - | |
| 0.54% | 4 M€ | -.--% | - | |
| 0.52% | 1 M€ | -.--% | ||
| 0.52% | 284 M€ | -.--% | ||
| 0.51% | 29 M€ | -.--% | - |
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.82
USD
Average target price
31.94
USD
Spread / Average Target
+10.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.10% | 161B | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.89% | 124B |
- Stock Market
- Equities
- PFE Stock
- Funds and ETFs Pfizer, Inc.
